A Canadian tertiary‑care study applying optical genome mapping (OGM) as a first‑line test identified previously undetected structural variants in nearly 20% of acute leukemia patients. Published in The Journal of Molecular Diagnostics, the work compared OGM to conventional cytogenetics and highlighted clinically actionable variants missed by standard workflows. Investigators argue OGM’s higher resolution could change diagnostic algorithms, refine prognosis and alter therapy selection in hematologic malignancies. The study frames OGM as a potential replacement or adjunct to karyotyping and fluorescence in situ hybridization for acute leukemia workups.